Sign In
Buy CLLS
$3.09
-0.290 (-8.58%)
At Close: Jun 03, 2026
Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs
02:48pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma
Monthly information on share capital and company voting rights
08:30pm, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08:30pm, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022
08:35pm, Monday, 23'rd May 2022 GlobeNewswire Inc.
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving
L’Assemblée Générale Mixte de Cellectis se tiendra le 28 juin 2022
08:35pm, Monday, 23'rd May 2022 GlobeNewswire Inc.
NEW YORK, 23 mai 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d’édition de
Why Cellectis' Shares Rose 22.7% This Week
11:35pm, Friday, 20'th May 2022 The Motley Fool
The company bucked the recent downward trend for biotech companies.
Why Cellectis' Shares Rose 22.7% This Week
07:35pm, Friday, 20'th May 2022
The company bucked the recent downward trend for biotech companies.
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022
02:13pm, Wednesday, 18'th May 2022 Benzinga
Upgrades
According to William Blair, the prior rating for On Holding AG (NYSE:ONON) was changed from Sell to Hold. At the moment, the stock has a 52-week-high of $55.87 and a 52-week-low of $16.38. O
Cellectis présente des données de recherche d’une nouvelle cellule CAR T universelle au congrès annuel de l’ASGCT
12:15pm, Monday, 16'th May 2022 GlobeNewswire Inc.
NEW YORK, 16 mai 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génom
Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
12:15pm, Monday, 16'th May 2022 GlobeNewswire Inc.
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Cellectis S.A.'s (CLLS) CEO Andre Choulika on Q1 2022 Results - Earnings Call Transcript
11:11am, Friday, 13'th May 2022
Cellectis S.A. (NASDAQ:CLLS ) Q1 2022 Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Carrie Browns
Cellectis publie ses résultats financiers du premier trimestre 2022
08:32pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
• Les données précliniques du produit candidat UCART20x22 présentées à l’AACR établissent une preuve de concept avec une solide activité anti-tumorale in vitro et in vivo
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
08:31pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
◦ UCART20x22 preclinical data presented at AACR demonstrated PoC with robust in vitro and in vivo anti-tumor activity
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08:43pm, Tuesday, 10'th May 2022 GlobeNewswire Inc.
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)
Monthly information on share capital and company voting rights
08:43pm, Tuesday, 10'th May 2022 GlobeNewswire Inc.
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
